USD 0.27
(0.33%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -12.99 USD | 50.58% |
2022 | -25.98 USD | 89.53% |
2021 | -248.22 USD | 76.6% |
2020 | -1060.77 USD | 80.41% |
2019 | -5416.22 USD | -29.71% |
2018 | -4175.51 USD | -127.59% |
2017 | -1834.66 USD | -322.77% |
2016 | -433.96 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.36 USD | -278.15% |
2024 Q2 | -0.56 USD | -1447.22% |
2023 Q2 | -0.29 USD | 98.81% |
2023 Q1 | -24.35 USD | -544.18% |
2023 FY | - USD | 50.58% |
2023 Q4 | -0.10 USD | 66.0% |
2023 Q3 | -0.28 USD | 3.45% |
2022 Q1 | -13.71 USD | 77.69% |
2022 FY | - USD | 89.53% |
2022 Q4 | -3.78 USD | 13.3% |
2022 Q3 | -4.36 USD | 66.79% |
2022 Q2 | -13.13 USD | 4.23% |
2021 Q2 | -64.18 USD | 48.25% |
2021 Q4 | -61.46 USD | -83.03% |
2021 FY | - USD | 76.6% |
2021 Q3 | -33.58 USD | 47.68% |
2021 Q1 | -124.03 USD | 31.24% |
2020 FY | - USD | 80.41% |
2020 Q2 | -535.50 USD | 23.4% |
2020 Q4 | -180.38 USD | -10.63% |
2020 Q3 | -163.05 USD | 69.55% |
2020 Q1 | -699.07 USD | 22.46% |
2019 Q3 | -1628.46 USD | -12.0% |
2019 Q2 | -1454.04 USD | -0.62% |
2019 Q1 | -1445.14 USD | 1.79% |
2019 FY | - USD | -29.71% |
2019 Q4 | -901.55 USD | 44.64% |
2018 Q2 | -909.53 USD | -227.03% |
2018 FY | - USD | -127.59% |
2018 Q4 | -1471.48 USD | -100.9% |
2018 Q1 | -278.12 USD | 13.02% |
2018 Q3 | -732.44 USD | 19.47% |
2017 Q4 | -319.74 USD | -80.0% |
2017 Q2 | -1165.44 USD | -579.0% |
2017 Q1 | -171.64 USD | 0.0% |
2017 Q3 | -177.63 USD | 84.76% |
2017 FY | - USD | -322.77% |
2016 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Perspective Therapeutics, Inc. | -0.10 USD | -12890.0% |
Electromed, Inc. | 0.60 USD | 2265.0% |
Senseonics Holdings, Inc. | -0.11 USD | -11709.091% |
Xtant Medical Holdings, Inc. | 0.01 USD | 236281.818% |